(AONC) American Oncology Network - Ratings and Ratios

American Oncology Network, Inc. operates as a critical component in the US oncology care landscape, delivering comprehensive management services to cancer patients through its subsidiaries. By providing an integrated suite of services including laboratory testing, in-house pathology, specialty pharmacy services, and care management support, the company addresses the complex needs of oncology patients. The incorporation in 2017 and subsequent growth underscores the rising demand for specialized oncology services, positioning AONC as a relatively new but significant player in the healthcare sector, headquartered in Fort Myers, Florida. For more information, visit their official website at https://www.aoncology.com.

Analyzing AONCs market presence, its categorized under the Health Care Services sub-industry as per GICS, with its common stock listed on NASDAQ under the ticker symbol AONC. The companys operational focus on oncology care aligns with the growing need for specialized healthcare services, suggesting potential for sustained growth.

Examining the , AONCs stock price is currently at $6.00, slightly above its SMA20 at $5.99, indicating a potential bullish trend. The stock is trading above its SMA50 ($5.44) and significantly above its SMA200 ($4.43), reinforcing the positive trend. The ATR of 0.39, representing 6.51% of the last price, suggests moderate volatility. The stock is near its 52-week high of $6.55 and far above its 52-week low of $1.05, indicating strong recent performance.

From a fundamental standpoint, AONC has a market capitalization of $190.11M USD and a Return on Equity (RoE) of 25.45%, indicating efficient use of shareholder capital. The absence of P/E and Forward P/E ratios complicates traditional valuation, potentially due to negative earnings or significant reinvestment in growth.

Forecasting AONCs trajectory, the combination of its strong recent stock performance, moderate volatility, and efficient capital use suggests potential for continued growth. The oncology services market is likely to expand due to the aging population and increasing cancer incidence. If AONC maintains its operational efficiency and continues to grow its service offerings, it could see further appreciation in stock value. A potential target could be a 10% increase to $6.60, aligning with its recent high and reflecting continued positive momentum. However, this forecast hinges on the companys ability to sustain its RoE and navigate the healthcare regulatory landscape effectively.